研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

全面综述新型免疫治疗靶点:富含亮氨酸重复序列的8A/容量调节阴离子通道。

Comprehensive review on the novel immunotherapy target: Leucine-rich repeat-containing 8A/volume-regulated anion channel.

发表日期:2024
作者: Yaohua Hu, Jing Qin, Yifan Ma, Runze Yang, Xinyu Liu, Changhong Shi
来源: International Journal of Biological Sciences

摘要:

富含亮氨酸的重复序列 8A (LRRC8A) 是容量调节阴离子通道 (VRAC) 的关键组成部分,可影响各种免疫细胞的重要稳态过程。这些过程包括细胞体积和膜电位的调节以及促进用作抗癌药物和免疫刺激因子的有机制剂的运输。因此,了解LRRC8A的结构与功能关系,探索其在免疫中的生理作用,评估其治疗疾病的功效,并推进调节其活性的化合物的开发是重要的研究前沿。本综述强调了LRRC8A的新兴领域,概述了其结构和功能,并总结了其在免疫细胞发育和免疫细胞介导的抗病毒和抗肿瘤作用中的作用。此外,它还探索了 LRRC8A 作为免疫治疗靶点的潜力,为解决持续存在的挑战和未来的研究方向提供了见解。© 作者。
Leucine-rich repeat-containing 8A (LRRC8A) is a key component of the volume-regulated anion channel (VRAC) that influences essential homeostatic processes in various immune cells. These processes include the regulation of cell volume and membrane potential and the facilitation of the transport of organic agents used as anticancer drugs and immune-stimulating factors. Therefore, understanding the structure-function relationship of LRRC8A, exploring its physiological role in immunity, assessing its efficacy in treating diseases, and advancing the development of compounds that regulate its activity are important research frontiers. This review emphasized the emerging field of LRRC8A, outlined its structure and function, and summarized its role in immune cell development and immune cell-mediated antiviral and antitumor effects. Additionally, it explored the potential of LRRC8A as an immunotherapeutic target, offering insights into resolving persistent challenges and future research directions.© The author(s).